Biosensors makes Singapore public debut
Singapore medical technology company Biosensors International made its debut in the public bond market at the start of the week, raising S$300m ($244.9m).
It sold the deal through its subsidiary Biosensors Investment, after picking Credit Suisse and Standard Chartered as bookrunners. The two banks drummed up enough demand to close a S$300m 4.875% January 2019 bond at par, an impressive outcome for a debut issuer in Singapore dollars, said a banker ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org